Cigna Group stock trades near consensus targets as analysts stick with Moderate Buy
Published on 09/19/2026 at 17:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cigna Group stock (ISIN US1255231003) is trading in the mid-USD 270s as of September 18, 2026, leaving a visible gap to the health services company’s average analyst price target above USD 330 and keeping valuation in focus for investors.
Analyst consensus underpins Cigna Group stock
According to MarketBeat on September 19, 2026, Cigna Group carries a consensus rating of Moderate Buy based on 23 analyst opinions, with 15 Buy and 8 Hold recommendations and no Sell ratings in the mix. The same overview cites an average price target of USD 337.10, implying about 22.5 percent upside from a contemporaneous share price of USD 275.21 in its dataset. Analyst detail referenced by MarketBeat on September 19, 2026 likewise highlights a Moderate Buy consensus and the same USD 337.10 average target versus a reported trading price of USD 275.57, reinforcing the message of double-digit expected upside.
Additional valuation work compiled by Simply Wall St and summarized on September 18, 2026 points to an average one-year analyst price target of about USD 340.50 across 24 analysts, with the highest individual target around USD 400 and the lowest near USD 290. In that snapshot, the average target sat roughly 21.9 percent above a share price of about USD 279.27, suggesting that much of the sell-side community still sees the shares as more than 20 percent undervalued relative to their fundamental assessment.
Recent performance and valuation context
Per data shown by MarketBeat on September 19, 2026, Cigna Group stock traded in a daily range of USD 273.74 to USD 276.15, with a current market capitalization of about USD 72.77 billion and a trailing price-to-earnings ratio of 11.39. The portal’s overview also shows a 52-week trading band between USD 239.51 and USD 315.47, placing the latest price near the middle of that one-year range and leaving around USD 40 of headroom to the 52-week high. A separate comparison snapshot from Pluang on September 19, 2026 lists Cigna Group trading at USD 275.28, down 1.84 percent on the day, with a market capitalization of about USD 72.74 billion, which is broadly consistent with the MarketBeat figures and supports the interpretation that the shares are consolidating below recent highs.
From a broader valuation standpoint, coverage highlighted by Zacks Investment Research on September 18, 2026 notes that Cigna trades at a forward price-to-earnings ratio of 8.47, compared with an industry average around 15.27. That implies a discount of roughly 44 percent to the sector’s typical earnings multiple, even as the Zacks Consensus Estimate for Cigna’s 2026 earnings is pegged at USD 30.51 per share, indicating 2.3 percent growth from the prior year. In other words, the stock is priced below peers on standard valuation metrics while consensus still anticipates modest earnings expansion.
Earnings backdrop and AI-driven strategy
The current analyst stance is supported by what recent coverage describes as solid underlying earnings and cash-flow power. In the context article published on September 18, 2026, Simply Wall St points to Cigna Group’s earnings power and cash-flow profile as key reasons why many analysts expect positive total returns over the coming year, even if the shares have moved only gradually in recent months. While that overview does not restate specific quarterly revenue or profit figures, it places emphasis on normalized earnings and free cash flow as supporting pillars for the valuation case.
Strategically, Zacks commentary distributed via The Globe and Mail on September 18, 2026 highlights Cigna’s push to apply artificial intelligence across its health services platform as a potential lever to help rein in rising healthcare costs. The article notes that Cigna shares have risen 4.3 percent over the past six months, compared with an industry growth rate of 36.4 percent, underscoring that while the stock has generated a positive return, it has lagged a fast-rising peer group. Zacks assigns the shares a Rank 3 (Hold) despite the valuation discount, reflecting a view that the AI initiatives and earnings outlook are balanced by competitive and regulatory risks in the wider managed-care and health services landscape.
Risks and positioning for investors
For investors, the key quantitative reference points as of mid-September 2026 are the roughly 22 to 23 percent upside embedded in the USD 337.10 consensus price target versus a share price around USD 275, the forward earnings multiple of 8.47 relative to an industry average of 15.27, and the 52-week high of USD 315.47 that marks the upper end of the recent trading range. These figures suggest that the market is pricing in some caution on growth and policy risk even as many analysts see scope for re-rating if earnings and cash-flow trends remain intact. At the same time, the six-month share-price gain of 4.3 percent compared with an industry increase of 36.4 percent, as described by Zacks, points to relative underperformance that could either signal an opportunity for mean reversion or a more skeptical stance by investors toward Cigna’s specific risk profile.
Current coverage also emphasizes that consensus earnings expectations for 2026 call for 2.3 percent year-on-year growth in earnings per share to USD 30.51, according to the Zacks framework. For a stock trading a bit above USD 275, that implies a forward earnings yield of just over 11 percent, which may appeal to income and value-oriented investors when combined with Cigna’s dividend and buyback policies. However, the Hold rating from Zacks alongside the Moderate Buy aggregate rating across 23 analysts shows that opinions are not uniformly bullish, and that the path to closing the gap between price and targets will depend on execution in areas such as AI-enabled care management, cost control, and regulatory developments.
Stock level and market data
As of the most recent trading data consolidated on September 19, 2026, Cigna Group stock is quoted around USD 275 on the New York Stock Exchange, with intraday trading ranges between roughly USD 273.74 and USD 276.15 and a market capitalization near USD 72.7 billion in USD terms. The shares sit between a 52-week low of USD 239.51 and a 52-week high of USD 315.47 on that venue, and analysts’ average price target of USD 337.10 would, if reached, place the stock modestly above its one-year high and about 22 percent above the latest price. For investors monitoring entry and exit points, this combination of mid-range current pricing, discounted earnings multiple and double-digit implied upside relative to consensus targets frames the near-term debate around Cigna Group stock.
Cigna Group stock key data
- Company: The Cigna Group Inc.
- ISIN: US1255231003
- Ticker: CI
- Trading venue: NYSE
- Price (as of September 19, 2026): 275.28 USD
- Market capitalization: 72.77 billion USD (as of September 19, 2026)
- Sector / Industry: Health Services / Managed Care
- Index membership: S&P 500
